194 related articles for article (PubMed ID: 33051199)
1. Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain.
Rodríguez López M; Megías Vericat JE; Albo López C; Bonanad S
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33051199
[TBL] [Abstract][Full Text] [Related]
2. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
[TBL] [Abstract][Full Text] [Related]
3. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
[TBL] [Abstract][Full Text] [Related]
4. Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.
Le Quellec S; Enjolras N; Perot E; Girard J; Negrier C; Dargaud Y
Thromb Haemost; 2018 Dec; 118(12):2053-2063. PubMed ID: 30453348
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
[TBL] [Abstract][Full Text] [Related]
6. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
[TBL] [Abstract][Full Text] [Related]
7. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.
Oldenburg J; Yan S; Maro G; Krishnarajah G; Tiede A
Curr Med Res Opin; 2020 Jan; 36(1):9-15. PubMed ID: 31469321
[No Abstract] [Full Text] [Related]
8. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
[No Abstract] [Full Text] [Related]
9. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
10. Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report.
Álvarez-Román MT; Merchán RD; Mellado RCR; Jiménez-Yuste V
Curr Opin Hematol; 2023 Sep; 30(5):175-179. PubMed ID: 37522479
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a recombinant factor IX molecule fused to coagulation factor XIII-B subunit.
Desage S; Leuci A; Enjolras N; Holle LA; Singh S; Delavenne X; Wolberg AS; Biswas A; Dargaud Y
Haemophilia; 2023 Nov; 29(6):1483-1489. PubMed ID: 37707428
[TBL] [Abstract][Full Text] [Related]
12. Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion
Lyseng-Williamson KA
Drugs; 2017 Jan; 77(1):97-106. PubMed ID: 27988873
[TBL] [Abstract][Full Text] [Related]
13. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
[TBL] [Abstract][Full Text] [Related]
14. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
[TBL] [Abstract][Full Text] [Related]
16. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice.
Mancuso ME; Oldenburg J; Boggio L; Kenet G; Chan A; Altisent C; Seifert W; Santagostino E
Haemophilia; 2020 Jul; 26(4):637-642. PubMed ID: 32542961
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
Martinowitz U; Lubetsky A
Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
